The Royal Pharmaceutical Society of Great Britain has branded plans to give general practitioners a financial incentive to prescribe fewer medicines to patients as "irresponsible bribery that potentially places patients at risk." The joint scheme will see profits from cutting drugs bills shared between GPs and a private company, Assura, which is currently bidding to take over the prescribing budgets at two National Health Service primary care trusts.
The RPSGB's director of policy and communications, David Pruce, said: "Assura's agreements with PCTs to give GPs financial kick-backs when they prescribe cheaper, generic drugs amount to plain bribery." He added that "paying doctors to prescribe cheaper drugs is the wrong approach. Prescribing is a core role for GPs and the proposals to reward doctors who change their prescribing habits when it may not be in the best interests of patients is unacceptable."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze